LB Pharmaceuticals Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by LB Pharmaceuticals Inc. (Nasdaq: LBRX) on September 15, 2026. The filing discloses the appointment of Susan G. Kozauer, M.D., as the Company's Chief Medical Officer, effective September 14, 2026. Dr. Kozauer previously served as Senior Vice President, Head of Clinical Development at Centessa Pharmaceuticals.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment terms.
Material Changes
The primary material change is the addition of a new senior executive officer. The filing details the specific compensation package negotiated for Dr. Kozauer, which includes:
- Base Salary: $515,000 annually.
- Target Bonus: 40% of the annual base salary.
- Sign-on Bonus: $150,000 total, with 50% payable within 30 days of the start date and the remaining 50% split over the first two anniversaries, subject to continued employment.
- Equity Grant: An option to purchase 200,000 shares of common stock, vesting over four years (25% on the first anniversary, monthly thereafter).
Outlook, Risks, and Contingencies
The filing outlines specific severance contingencies tied to the Employment Agreement:
- Standard Termination: If terminated without cause or resigns for good reason (outside a change of control), Dr. Kozauer is entitled to nine months of base salary and COBRA premiums for up to nine months.
- Change of Control: If terminated without cause or resigns for good reason within 12 months of a change of control, benefits include a lump sum of one year's base salary plus 150% of the target bonus, 12 months of COBRA premiums, and acceleration of all unvested equity awards.
The filing notes that the full Employment Agreement will be filed as an exhibit to the Quarterly Report on Form 10-Q for the quarter ending September 30, 2026.
Investor Verification Checklist
- Verify the full text of the Employment Agreement when filed as an exhibit to the Q3 2026 Form 10-Q.
- Confirm the vesting schedule and exercise price of the 200,000 share option grant.
- Review the Company's cash position to assess the impact of the $150,000 sign-on bonus and ongoing salary obligations.
- Monitor future filings for any updates regarding Dr. Kozauer's clinical development strategy.